Effect of hyperbaric oxygen therapy combined with Bosentan on the serum expressions of NT-proBNP and galectins-3 in children with congenital heart disease and severe pulmonary hypertension
10.3760/cma.j.cn311847-20200412-00142
- VernacularTitle:高压氧联合波生坦治疗对先天性心脏病伴重度肺动脉高压患儿血清NT-proBNP及galectins-3表达的影响
- Author:
Ruihua YANG
1
;
Junying WANG
1
;
Zhenfang WANG
1
;
Jieqiong LIU
1
;
Xiaoping ZHANG
1
;
Tao CUI
1
;
Ye SUN
1
;
Lihua LIU
1
;
Jing SUN
1
Author Information
1. 030013 太原，山西省儿童医院心内科
- Publication Type:Journal Article
- Keywords:
Hyperbaric oxygen;
Bosentan;
Congenital heart disease;
Severe pulmonary arterial hypertension;
NT-proBNP;
Galectins-3
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2021;28(4):455-459
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of hyperbaric oxygen therapy combined with Bosentan on the serum expressions of NT-proBNP and galectins-3 in children with congenital heart disease (CHD) and severe pulmonary arterial hypertension (PAH).Methods:The clinical data of 80 children with CHD and severe PAH admitted to the Department of Cardiology of Children’s Hospital of Shanxi from January 2015 to December 2019 were collected. According to the treatment, the children were divided into observation group ( n=40) and control group ( n=40). The control group was given Bosentan and conventional treatment, and the observation group was given hyperbaric oxygen therapy on the basis of the treatments in the control group. The therapeutic effects of the two groups were observed after three courses of treatment. Mean pulmonary arterial pressure (MPAP), mean systemic arterial pressure (MSAP), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR), and pulmonary artery pressure/aortic pressure (Pp/Ps) were measured by echocardiography before and after treatment. Two milliliters of radial artery blood were collected on an empty stomach before and after treatment, and partial pressure of carbon dioxide (PaCO 2), partial pressure of oxygen (PaO 2), and oxygenation index (OI) were measured by blood gas analyzer. Cardiac output (CO) per minute and cardiac index (CI) were calculated by echocardiography. Serum levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) and galectins-3 were detected by ELISA. The therapeutic effect, hemodynamic indexes, cardiac function, and the levels of NT-proBNP and galectins-3 were observed. Results:After three courses of treatment, the total effective rate in the observation group (90.0%) was significantly higher than that in the control group (70.0%), and the difference was statistically significant ( P<0.05). The levels of MPAP, MSAP, SVR, PVR, and Pp/Ps in the two groups were decreased after treatment, and those in the observation group decreased more significantly after treatment than those in the control group, with statistically significant differences ( P<0.05); PaO 2, OI, CI, and CO in the two groups were significantly higher than those before treatment, and those in the observation group were significantly higher than those in the control group after treatment ( P<0.05). The levels of serum NT-proBNP and galectins-3 in the two groups were significantly decreased, and the levels of serum NT-proBNP and galectins-3 in the observation group were significantly lower than those in the control group after treatment ( P<0.05). Conclusion:Hyperbaric oxygen combined with Bosentan therapy is effective in treating patients with CHD and severe PAH. It can significantly improve the hemodynamics indexes of pulmonary circulation and cardiac function, reduce the expression levels of NT-proBNP and galectins-3, and is conducive to prognosis.
